Stevo Julius

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi request reprint Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
    Stevo Julius
    University of Michigan, Ann Arbor, USA
    Lancet 363:2022-31. 2004
  2. ncbi request reprint Feasibility of treating prehypertension with an angiotensin-receptor blocker
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
    N Engl J Med 354:1685-97. 2006
  3. ncbi request reprint The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, 24 Frank Lloyd Wright Dr, PO Box 322, Lobby M, Ann Arbor, MI 48106, USA
    Hypertension 48:385-91. 2006
  4. doi request reprint Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial
    Sverre E Kjeldsen
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
    Blood Press 17:170-7. 2008
  5. ncbi request reprint Blood pressure lowering only or more? Has the jury reached its verdict?
    Stevo Julius
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Am J Cardiol 100:32J-37J. 2007
  6. doi request reprint Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension
    Stevo Julius
    University of Michigan, Ann Arbor, USA
    Am J Cardiol 109:685-92. 2012
  7. ncbi request reprint Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial
    Sverre E Kjeldsen
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Hypertens 24:1405-12. 2006
  8. ncbi request reprint Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study
    Stevo Julius
    Department of Internal Medicine, Division of Hypertension, University of Michigan Medical Center, 3918 Taubman Center, Ann Arbor, MI 48109 0356, USA
    J Am Coll Cardiol 43:1047-55. 2004
  9. ncbi request reprint VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk
    Stevo Julius
    Department of Internal Medicine, Division of Hypertension, University of Michigan Health System, Ann Arbor, Michigan 48109 0356, USA
    Am J Hypertens 16:544-8. 2003
  10. doi request reprint A Bayesian sensitivity model for intention-to-treat analysis on binary outcomes with dropouts
    Niko A Kaciroti
    Center for Human Growth and Development, University of Michigan, Ann Arbor, MI 48109, USA
    Stat Med 28:572-85. 2009

Collaborators

Detail Information

Publications69

  1. ncbi request reprint Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
    Stevo Julius
    University of Michigan, Ann Arbor, USA
    Lancet 363:2022-31. 2004
    ....
  2. ncbi request reprint Feasibility of treating prehypertension with an angiotensin-receptor blocker
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
    N Engl J Med 354:1685-97. 2006
    ..Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension...
  3. ncbi request reprint The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, 24 Frank Lloyd Wright Dr, PO Box 322, Lobby M, Ann Arbor, MI 48106, USA
    Hypertension 48:385-91. 2006
    ..Moreover, these findings support the feasibility of comparative prospective trials in lower-risk hypertensive patients...
  4. doi request reprint Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial
    Sverre E Kjeldsen
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
    Blood Press 17:170-7. 2008
    ..We conclude that valsartan compared with amlodipine reduces the risk of developing diabetes mellitus, particularly in hypertensive patients with the highest susceptibility for development of diabetes...
  5. ncbi request reprint Blood pressure lowering only or more? Has the jury reached its verdict?
    Stevo Julius
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Am J Cardiol 100:32J-37J. 2007
    ..Clinical trials in mild forms of hypertension are essential to investigate the non-blood pressure effects of antihypertensive agents...
  6. doi request reprint Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension
    Stevo Julius
    University of Michigan, Ann Arbor, USA
    Am J Cardiol 109:685-92. 2012
    ..This effect was not modified by good blood pressure control. It is not yet known whether a therapeutic reduction of HR would improve cardiovascular prognosis...
  7. ncbi request reprint Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial
    Sverre E Kjeldsen
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Hypertens 24:1405-12. 2006
    ..Type 2 diabetes is emerging as a major health problem, which tends to cluster with hypertension in individuals at high risk of cardiovascular disease...
  8. ncbi request reprint Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study
    Stevo Julius
    Department of Internal Medicine, Division of Hypertension, University of Michigan Medical Center, 3918 Taubman Center, Ann Arbor, MI 48109 0356, USA
    J Am Coll Cardiol 43:1047-55. 2004
    ..We report on a subanalysis of the effects of losartan and atenolol on cardiovascular events in black patients in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study...
  9. ncbi request reprint VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk
    Stevo Julius
    Department of Internal Medicine, Division of Hypertension, University of Michigan Health System, Ann Arbor, Michigan 48109 0356, USA
    Am J Hypertens 16:544-8. 2003
    ..The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study compares cardiovascular outcomes in 15,314 eligible patients from 31 countries randomized to valsartan or amlodipine-based treatment...
  10. doi request reprint A Bayesian sensitivity model for intention-to-treat analysis on binary outcomes with dropouts
    Niko A Kaciroti
    Center for Human Growth and Development, University of Michigan, Ann Arbor, MI 48109, USA
    Stat Med 28:572-85. 2009
    ..Such parameterization is intuitive and easy to use in sensitivity analysis; it also incorporates most of the available methods as special cases. The model is applied to TRial Of Preventing HYpertension...
  11. doi request reprint Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Hypertens 30:2213-22. 2012
    ..To determine whether blood pressure (BP) control in hypertensive patients achieved with combination drug therapy provides the same cardiovascular benefits as with single-agent therapy...
  12. ncbi request reprint Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY study
    Shawna D Nesbitt
    Department of Internal Medicine, Division of Hypertension, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8899, USA
    Am J Hypertens 18:980-5. 2005
    ..5 % (men) and >or=41.2% (women)...
  13. ncbi request reprint Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy
    Sverre E Kjeldsen
    Department of Internal Medicine, Dividsion of Hypertension, University of Michigan, Ann Arbor, USA
    JAMA 288:1491-8. 2002
    ..Drug intervention in placebo-controlled trials has been beneficial in isolated systolic hypertension...
  14. ncbi request reprint Trial of preventing hypertension: design and 2-year progress report
    Stevo Julius
    Division of Cardiovascular Medicine, University of Michigan Medical Center 3918 TC, 1500 E Medical Center Dr, Ann Arbor, MI 48109 0500, USA
    Hypertension 44:146-51. 2004
    ..In this article, we describe baseline characteristics of TROPHY subjects and discuss novel analytical issues and statistical approaches to evaluate the findings in this trial of primary prevention of hypertension...
  15. ncbi request reprint Should the results of TROPHY affect the JNC 7 definition of prehypertension?
    Stevo Julius
    Internal Medicine and Physiology, Division of Cardiovascular Medicine, University of Michigan, 24 Frank Lloyd Wright Drive, Lobby M, 3rd Floor, Ann Arbor, MI 48106, USA
    Curr Hypertens Rep 9:202-5. 2007
    ..By the present JNC definition, only one quarter of adult men have normal blood pressure. Removing the disease label from another 28% would appropriately focus attention on high-risk prehypertension...
  16. ncbi request reprint Antihypertensive utility of perindopril in a large, general practice-based clinical trial
    Stevo Julius
    Division of Hypertension, University of Michigan, Ann Arbor, MI 48109, USA
    J Clin Hypertens (Greenwich) 6:10-7. 2004
    ..Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal...
  17. ncbi request reprint TROPHY study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension
    Stevo Julius
    University of Michigan, Ann Arbor, Michigan, USA
    J Am Soc Hypertens 2:39-43. 2008
    ..009; original report 16%; P < .007). The new definition resulted in a lower incidence of hypertension, but the outcomes were remarkably similar with both definitions and confirmed our original findings...
  18. ncbi request reprint A "gender blind" relationship of lean body mass and blood pressure in the Tecumseh study
    Stevo Julius
    Division of Hypertension, University of Michigan, Ann Arbor 48109 0356, USA
    Am J Hypertens 15:258-63. 2002
    ..Body size correlates positively with blood pressure (BP) but there is controversy about the roles of obesity versus muscularity in this relationship...
  19. doi request reprint In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension
    Stevo Julius
    aDivision of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan bDepartment of Medicine, Medical University of South Carolina, Charleston, South Carolina cCenter for Human Growth and Development, University of Michigan, Ann Arbor, Michigan dDepartmentof Internal Medicine, University of Texas Southwestern, Dallas, Texas eDivision of Cardiovascular Disease, Scripps Clinic, La Jolla, California, USA
    J Hypertens 32:251-9. 2014
    ....
  20. pmc A Bayesian model for time-to-event data with informative censoring
    Niko A Kaciroti
    Department of Biostatistics, Center for Human Growth and Development, University of Michigan, Ann Arbor, MI 48109, USA
    Biostatistics 13:341-54. 2012
    ..The proposed approach is applied to data from the TRial Of Preventing HYpertension...
  21. doi request reprint Tachycardia in hypertension: a saga of progress despite prejudice, confusion, and inertia
    Stevo Julius
    University of Michigan Cardiovascular Center, Ann Arbor, MI, USA
    Prog Cardiovasc Dis 52:26-30. 2009
    ..The best way to convince the public is to demonstrate that lowering the heart rate with a drug without influence on blood pressure reduces cardiovascular events...
  22. ncbi request reprint Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension
    Mariaconsuelo Valentini
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    J Hypertens 22:1999-2006. 2004
    ..beta-adrenoceptor down-regulation has been described in hypertension. We tested the hypothesis that chronic sympathetic overactivity impairs beta-adrenergic-mediated thermogenesis and thereby favours gain of weight in hypertension...
  23. ncbi request reprint Does life-long reduction in low-density lipoprotein cholesterol reduce the risk of new-onset hypertension?
    Franz H Messerli
    Am J Cardiol 98:1122. 2006
  24. ncbi request reprint Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension
    Peter M Okin
    Greenberg Division of Cardiology, Weill Medical College of Cornell University, New York, NY 10021, USA
    JAMA 296:1242-8. 2006
    ..Although the presence and severity of electrocardiographic left ventricular hypertrophy (LVH) appear to predict development of AF, whether regression of electrocardiographic LVH is associated with a decreased incidence of AF is unclear...
  25. ncbi request reprint Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy
    Sverre E Kjeldsen
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    J Clin Hypertens (Greenwich) 8:487-92. 2006
    ..In conclusion, these agents are efficacious in antihypertensive therapy and can play an important role in the prevention or regression of left ventricular hypertrophy due to hypertension...
  26. ncbi request reprint Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study
    Jorge R Kizer
    Weill Medical College of Cornell University, New York, NY, USA
    Hypertension 45:46-52. 2005
    ....
  27. ncbi request reprint Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study
    Peter M Okin
    Division of Cardiology, Department of Medicine, Cornell University Medical Center, New York, NY 10021, USA
    Circulation 113:1588-96. 2006
    ....
  28. ncbi request reprint Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial
    Alberto Zanchetti
    aCentro Interuniversitario di Fisiologia Clinica e Ipertensione, University of Milan, Istituto Auxologico Italiano and Ospedale Maggiore, Milan, Italy
    J Hypertens 24:2163-8. 2006
    ..Stroke incidence was non-significantly, and myocardial infarction was significantly lower in the amlodipine-based regimen, whereas cardiac failure was non-significantly lower on valsartan...
  29. ncbi request reprint Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy
    Ole Lederballe Pedersen
    Sygehus Viborg, Viborg, Denmark
    J Hypertens 25:707-12. 2007
    ..ABP was measured after 1 year in the trial, with the aim of evaluating comparability of ABP levels on valsartan (VAL) and amlodipine (AML)-based regimens...
  30. ncbi request reprint From TROPHY with pride
    Stevo Julius
    Am J Hypertens 20:342-3; author reply 343-5. 2007
  31. ncbi request reprint Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Hypertens 25:1473-9. 2007
    ..Reduced renal function is predictive of poor cardiovascular outcomes but the predictive value of different measures of renal function is uncertain...
  32. ncbi request reprint An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY)
    Setareh A Williams
    AstraZeneca LP, Wilmington, DE 19850, USA
    J Clin Hypertens (Greenwich) 10:436-42. 2008
    ..05). In TROPHY, patients with prehypertension had relatively high baseline HRQL, and HRQL was maintained with the angiotensin receptor blocker candesartan over both the 2-year treatment period and a total 4-year trial period...
  33. doi request reprint Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy
    Peter M Okin
    Greenberg Division of Cardiology, Weill Cornell Medical College, New York, NY 10021, USA
    Hypertension 52:100-6. 2008
    ....
  34. doi request reprint Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension
    Franz H Messerli
    Division of Cardiology, St Luke s Roosevelt Hospital, Columbia University College of Physicians and Surgeons, 1000 10th Ave, Suite 3B 30, New York, NY 10019, USA
    Circulation 117:2706-15; discussion 2715. 2008
  35. doi request reprint Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial
    Roland E Schmieder
    Department of Nephrology and Hypertension, University Erlangen Nuremberg, Erlangen, Germany
    J Hypertens 26:403-11. 2008
    ..Therefore, in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) a prespecified objective was to compare the effects of valsartan and amlodipine on new-onset AF...
  36. doi request reprint Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study
    Peter M Okin
    Greenberg Division of Cardiology, Weill Medical College of Cornell University, New York, New York, USA
    Am J Hypertens 21:273-9. 2008
    ..Although albuminuria and the electrocardiographic (ECG) strain pattern each predict development of heart failure (HF), whether combining albuminuria and strain improves prediction of new HF is unclear...
  37. ncbi request reprint Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients
    Peter M Okin
    Weill Medical College of Cornell University, New York, New York 10021, USA
    Ann Intern Med 147:311-9. 2007
    ..However, whether reduction of electrocardiographic LVH is associated with decreased heart failure is unclear...
  38. ncbi request reprint Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population
    Tonje A Aksnes
    Department of Cardiology, Ullevaal University Hospital, N 0407 Oslo, Norway
    Hypertension 50:467-73. 2007
    ....
  39. ncbi request reprint Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy
    Eigil Fossum
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    J Clin Hypertens (Greenwich) 8:169-73. 2006
    ..The difference in carotid plaque index increase between the treatment groups during 3 years of treatment could not be statistically linked to specific treatments in the present substudy...
  40. ncbi request reprint Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
    Lars H Lindholm
    Umea University Hospital, Sweden
    Lancet 359:1004-10. 2002
    ..In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients...
  41. ncbi request reprint Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
    Michael A Weber
    State University of New York, Brooklyn, NY, USA
    Lancet 363:2049-51. 2004
    ....
  42. ncbi request reprint Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients
    Peter M Okin
    Greenberg Division of Cardiology, Weill Medical College of Cornell University, 525 East 68th St, New York, NY 10021, USA
    Hypertension 44:48-54. 2004
    ..33, 95% CI 1.11 to 1.59). Thus, ECG strain is a marker of increased CV risk in hypertensive patients in the setting of aggressive blood pressure lowering, independent of baseline severity of ECG LVH...
  43. ncbi request reprint Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
    Bjorn Dahlof
    Sahlgrenska University Hospital Ostra, Gothenburg, Swede
    Lancet 359:995-1003. 2002
    ..We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death...
  44. ncbi request reprint The impact of serum uric acid on cardiovascular outcomes in the LIFE study
    Aud Høieggen
    Departments of Nephrology and Cardiology, Ullevaal University Hospital, Oslo, Norway
    Kidney Int 65:1041-9. 2004
    ..It has been suggested that the LIFE study results may be related to the effects of losartan on serum uric acid (SUA). SUA has been proposed as an independent risk factor for CV morbidity and death...
  45. ncbi request reprint Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial
    Jay N Cohn
    Cardiovascular Division, University of Minnesota Medical School, Box 508, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Am J Hypertens 17:134-8. 2004
    ..The prevalence of hypertension is greater in African Americans, and management of this condition presents challenges for practicing physicians...
  46. ncbi request reprint Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study
    Kristian Wachtell
    Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
    Ann Intern Med 139:901-6. 2003
    ..The partition values for urine albumin-creatinine ratio (UACR) used to identify microalbuminuria have been based on studies that predicted risk in diabetic patients...
  47. ncbi request reprint Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial
    Richard B Devereux
    Weill Medical College of Cornell University, New York, New York, USA
    Ann Intern Med 139:169-77. 2003
    ....
  48. ncbi request reprint Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study
    Peter M Okin
    Department of Medicine, Cornell University Medical Center, 525 East 68th St, New York, NY 10021, USA
    Circulation 108:684-90. 2003
    ..However, uncertainty persists as to how best to regress ECG LVH...
  49. ncbi request reprint Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers?
    Alberto Zanchetti
    Centro di Fisiologia Clinica e Ipertensione, Universita di Milano, Ospedale Maggiore, Istituto Auxologico Italiano, Italy
    J Hypertens 21:797-804. 2003
    ..We investigated whether the benefits of intensive DBP lowering could be extended to other subgroups, and whether there are hypertensives in whom the risk of aggressive DBP lowering may outnumber the benefits...
  50. ncbi request reprint Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
    Lars H Lindholm
    Steno Diabetes Centre, Gentofte, Denmark
    J Hypertens 20:1879-86. 2002
    ..There has been uncertainty about the risk of new-onset diabetes in hypertensive individuals treated with different blood pressure-decreasing drugs...
  51. ncbi request reprint AT1 blockers: are there alternative pathways reducing cardiovascular risk? Introduction
    Peter A van Zwieten
    Departments of Pharmacotherapy, Cardiology and Cardiothoracal Surgery, Academic Medical Centre, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
    J Hypertens Suppl 20:S1. 2002
  52. ncbi request reprint Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint
    Peter M Okin
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Hypertens 15:663-71. 2002
    ..However, the high mortality associated with LVH in African American patients makes more accurate ECG detection of LVH in these patients a clinical priority...
  53. ncbi request reprint Can hypertension be prevented? The Danish Hypertension Prevention Project and the Trial of Prevention of Hypertension studies
    Karin Skov
    Department of Pharmacology, University of Aarhus, Aarhus, Denmark
    Curr Opin Cardiol 17:380-4. 2002
    ....
  54. ncbi request reprint Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy
    Hans Ibsen
    Glostrup University Hospital, Denmark
    J Hypertens 22:1805-11. 2004
    ....
  55. ncbi request reprint Clinical experience with perindopril in elderly hypertensive patients: a subgroup analysis of a large community trial
    Joel M Neutel
    Orange County Research Center, Tustin, California 92780, USA
    Am J Cardiovasc Drugs 4:335-41. 2004
    ..To evaluate the effectiveness and safety of perindopril in a subgroup of 3010 elderly (> or =65 years) hypertensive patients, who participated in a large US general practice-based community trial...
  56. ncbi request reprint The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study
    Eigil Fossum
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    J Am Coll Cardiol 46:770-5. 2005
    ..We conducted a subgroup analysis in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study to determine whether aspirin interacted with the properties of losartan, an angiotensin-II receptor antagonist...
  57. ncbi request reprint Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study
    Giovanni de Simone
    Department of Clinical and Experimental Medicine, Federico II University Hospital, Via S Pansini, No 5, 80131 Naples, Italy
    Circulation 111:1924-31. 2005
    ....
  58. ncbi request reprint Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy
    Frej Fyhrquist
    Helsinki University Central Hospital, Department of Medicine, and Minerva Institute for Medical Research, Helsinki, Finland
    Hypertension 45:580-5. 2005
    ..The risks in the losartan group also increased with increasing pulse pressure quartile, but were lower than those in the atenolol group, and were not significant...
  59. ncbi request reprint The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study
    Sverre E Kjeldsen
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    J Clin Hypertens (Greenwich) 7:152-8. 2005
    ..33) different from the atenolol group. These data suggest that losartan-based treatment is more effective than an atenolol-based treatment for patients with ISH and a high risk for stroke...
  60. ncbi request reprint Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy
    Michael H Olsen
    Department of Clinical Physiology and Nuclear Medicine, Glostrup University Hospital, Copenhagen, Denmark
    J Hypertens 23:891-8. 2005
    ..We hypothesized that treatment with losartan as compared to atenolol would improve insulin sensitivity through regression of peripheral vascular hypertrophy/rarefaction...
  61. ncbi request reprint Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study
    Henrik M Reims
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    Blood Press 13:376-84. 2004
    ..Smoking increased cardiovascular risk markedly in the LIFE study. The benefit of losartan vs atenolol is consistent with the overall conclusion of the LIFE study, although the treatment effect appeared largest in non-smokers...
  62. ncbi request reprint Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
    J Am Coll Cardiol 45:712-9. 2005
    ..This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF)...
  63. ncbi request reprint Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
    J Am Coll Cardiol 45:705-11. 2005
    ..We assessed the impact of antihypertensive treatment in hypertensive patients with electrocardiographic (ECG) left ventricular (LV) hypertrophy and a history of atrial fibrillation (AF)...
  64. ncbi request reprint Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure
    Brent M Egan
    Medical University of South Carolina, Charleston, South Carolina, USA
    Am J Hypertens 18:3-12. 2005
    ..Although insulin resistance and metabolic syndrome are often used synonymously, concordance is not established...
  65. ncbi request reprint Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study
    Hans Ibsen
    Glostrup University Hospital, Denmark
    Hypertension 45:198-202. 2005
    ..If albuminuria is not decreased by the patient's current antihypertensive and other treatment, further intervention directed toward blood pressure control and other modifiable risks should be considered...
  66. ncbi request reprint Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events
    Peter M Okin
    Department of Medicine, Division of Cardiology, Cornell University Medical Center, New York, NY 10021, USA
    JAMA 292:2343-9. 2004
    ..However, the predictive value of changes in the magnitude of electrocardiographic LVH criteria during antihypertensive therapy remains unclear...
  67. ncbi request reprint Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
    Sverre E Kjeldsen
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    Am Heart J 148:747-54. 2004
    ....
  68. ncbi request reprint Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting
    Paolo Palatini
    Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy
    J Hypertens 24:603-10. 2006
  69. ncbi request reprint Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy
    Paolo Palatini
    Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    Drugs 66:133-44. 2006
    ..Unfortunately, lowering of the heart rate is not a clinically recognised goal. Prospective trials investigating whether treatment of high heart rate can prevent cardiovascular events, notably in hypertensive patients, are warranted...